SHR-A1921 plus Avastin for triple-negative breast cancer with brain spread
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two drugs (SHR-A1921 and Avastin) to see if it can shrink or slow brain tumors caused by triple-negative breast cancer. It’s for people whose breast cancer has spread to the brain and haven’t had radiation to the brain yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have triple-negative breast cancer that has spread or come back and cannot be removed by surgery.
- You must have at least one brain tumor (1 cm or larger) that hasn't been treated with radiation yet. You can be on stable doses of steroids, mannitol, or seizure medicine.
- You need to have good organ function (kidney, liver, bone marrow, and heart) as shown by blood tests and an EKG.
- You cannot have had prior treatment with Avastin (bevacizumab) or any TROP-2 targeting ADC (like Trodelvy).
- You should be able to follow the study schedule and have a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) to treat triple-negative breast cancer that has spread to the brain. Triple-negative means the cancer cells lack three common markers, making it harder to treat with standard therapies.
This trial tests whether a combination of three drugs (SHR-A1811, pyrotinib, and bevacizumab) can help people with advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and stop them from growing.
This Phase 2 study tests a treatment for people with triple-negative breast cancer that has spread to the brain. It’s designed for situations where the cancer can’t be safely cured with surgery or focused radiation.
This study tests a combination of radiation therapy, chemotherapy drugs (platinum-based), and two immunotherapy medications (adebrelimab and bevacizumab) for triple-negative breast cancer that has spread to the brain. The goal is to shrink tumors and improve survival when surgery or standard radiation alone isn't an option.
This trial tests a new drug SHR-A2102 combined with other treatments for advanced or metastatic breast cancer. It aims to see if the combination is safe and effective.
This trial tests a combination of two drugs—SHR-A1921 (a targeted therapy) and Adebrelimab (an immunotherapy)—for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, PD-L1 positive). It aims to see if this combo can help when hormone therapy and chemotherapy haven't worked well enough.
Hear when a new Brain Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.